|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| 07-08 | Irlab board member James Gamgort buys shares for just under SEK 0.3m | FW |
| 07-01 | IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors | CI |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 191.5 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 14.47% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 191.5 | 191.5 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 14.47% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 1.88x | 1.35x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.88x | 1.35x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -6.94x | 5.14x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -6.06x | 5.75x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 102 | 141.8 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -27.6 | 37.3 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.6 | 33.3 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -32.6 | 33.3 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 1.288 | 1.288 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 23/2/22 | 23/2/23 | 7/2/24 | 12/2/25 | 25/2/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.04x | 12.53x | 26.21x | 0.57% | 1,051B | |
| 27.19x | 6.2x | 16.98x | 2.12% | 609B | |
| 33.15x | 7.52x | 15.43x | 2.7% | 450B | |
| 17.85x | 4.43x | 10.91x | 3% | 330B | |
| 21.66x | 5.55x | 13.44x | 2.84% | 284B | |
| 21.16x | 4.46x | 12.34x | 1.97% | 263B | |
| 14.45x | 5.41x | 11.15x | 3.44% | 223B | |
| 24.02x | 6.35x | 11.22x | 2.75% | 198B | |
| -48.37x | 5.78x | 31.95x | 2.42% | 167B | |
| Average | 16.24x | 6.47x | 16.62x | 2.42% | 397.23B | |
| Weighted average by Cap. | 24.01x | 7.82x | 18.33x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- IRLA.F Stock
- Valuation IRLAB Therapeutics AB
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
